666 related articles for article (PubMed ID: 34479364)
1. How I treat and prevent venous thrombotic complications in patients with lymphoma.
Schmidt RA; Lee AYY
Blood; 2022 Mar; 139(10):1489-1500. PubMed ID: 34479364
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
[TBL] [Abstract][Full Text] [Related]
5. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
6. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis.
Shin YE; Kumar A; Hwang M; Mackey M; Wu WK
Clin Drug Investig; 2022 Dec; 42(12):1075-1083. PubMed ID: 36315349
[TBL] [Abstract][Full Text] [Related]
8. Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
Verso M; Agnelli G
Thromb Res; 2020 Jul; 191 Suppl 1():S123-S127. PubMed ID: 32736770
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
11. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
[TBL] [Abstract][Full Text] [Related]
12. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
13. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Abdel-Razeq H; Finianos A; Taher AT
Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants in patients with cancer.
Bossaer JB; Covert KL
Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
16. Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.
Attard LM; Gatt A; Bertoletti L; Delluc A; Riva N
Vasc Health Risk Manag; 2022; 18():793-807. PubMed ID: 36268462
[TBL] [Abstract][Full Text] [Related]
17. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
Rojas-Hernandez CM; Oo TH
Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
[TBL] [Abstract][Full Text] [Related]
18. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
Song AB; Rosovsky RP; Connors JM; Al-Samkari H
Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation prescribing patterns in patients with cancer.
Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
